Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93


Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.

Redlich N, Robinson AM, Nickel KP, Stein AP, Wheeler DL, Adkins DR, Uppaluri R, Kimple RJ, Van Tine BA, Michel LS.

Cell Death Dis. 2018 Jan 5;9(1):5. doi: 10.1038/s41419-017-0029-0.


A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

Mota JM, Collier KA, Barros Costa RL, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA.

Oncotarget. 2017 Jun 13;8(51):89284-89306. doi: 10.18632/oncotarget.18467. eCollection 2017 Oct 24. Review.


Targeting protein quality control pathways in breast cancer.

Sannino S, Brodsky JL.

BMC Biol. 2017 Nov 16;15(1):109. doi: 10.1186/s12915-017-0449-4. Review.


siRNA-mediated inactivation of HER3 improves the antitumour activity and sensitivity of gefitinib in gastric cancer cells.

Yuan HH, Yang YN, Zhou JH, Li YJ, Wang LY, Qin JW, Liu T, Li ZZ, Zhou QX, Wei XL, Zhang TT, Huang P, Zhang WJ, Liu L, Du XX, Han Y.

Oncotarget. 2017 Apr 29;8(32):52584-52593. doi: 10.18632/oncotarget.17526. eCollection 2017 Aug 8.


Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).

Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, Pace E, Harms B, Kim J, Kearns J, Fulgham A, Burenkova O, Grantcharova V, Yarar D, Paragas V, Fitzgerald J, Wainszelbaum M, West K, Mathews S, Nering R, Adiwijaya B, Garcia G, Kubasek B, Moyo V, Czibere A, Nielsen UB, MacBeath G.

NPJ Syst Biol Appl. 2017 Jan 5;3:16034. doi: 10.1038/npjsba.2016.34. eCollection 2017. Review.


Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G.

Int J Mol Sci. 2017 Jul 14;18(7). pii: E1522. doi: 10.3390/ijms18071522. Review.


ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).

Hayes DA, Kunde DA, Taylor RL, Pyecroft SB, Sohal SS, Snow ET.

PLoS One. 2017 Jun 7;12(6):e0177919. doi: 10.1371/journal.pone.0177919. eCollection 2017.


Inhibition of HER3 activation and tumor growth with a human antibody binding to a conserved epitope formed by domain III and IV.

Schmitt LC, Rau A, Seifert O, Honer J, Hutt M, Schmid S, Zantow J, Hust M, Dübel S, Olayioye MA, Kontermann RE.

MAbs. 2017 Jul;9(5):831-843. doi: 10.1080/19420862.2017.1319023. Epub 2017 Apr 19.


Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer Cells.

Schardt JS, Oubaid JM, Williams SC, Howard JL, Aloimonos CM, Bookstaver ML, Lamichhane TN, Sokic S, Liyasova MS, O'Neill M, Andresson T, Hussain A, Lipkowitz S, Jay SM.

Mol Pharm. 2017 Apr 3;14(4):1047-1056. doi: 10.1021/acs.molpharmaceut.6b00919. Epub 2017 Mar 8.


In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct.

Bass TZ, Rosestedt M, Mitran B, Frejd FY, Löfblom J, Tolmachev V, Ståhl S, Orlova A.

Sci Rep. 2017 Feb 23;7:43118. doi: 10.1038/srep43118.


Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.

Shimizu T, Yonesaka K, Hayashi H, Iwasa T, Haratani K, Yamada H, Ohwada S, Kamiyama E, Nakagawa K.

Cancer Chemother Pharmacol. 2017 Mar;79(3):489-495. doi: 10.1007/s00280-016-3231-3. Epub 2017 Jan 31.


Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.

Liu JF, Ray-Coquard I, Selle F, Poveda AM, Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P, Siena S, Del Campo JM, Tabah-Fisch I, Pearlberg J, Moyo V, Riahi K, Nering R, Kubasek W, Adiwijaya B, Czibere A, Naumann RW, Coleman RL, Vergote I, MacBeath G, Pujade-Lauraine E.

J Clin Oncol. 2016 Dec 20;34(36):4345-4353. Epub 2016 Oct 23.


Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.

Schram AM, Iasonos A, Hyman DM.

J Clin Oncol. 2016 Dec 20;34(36):4312-4314. Epub 2016 Oct 23. No abstract available.


Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.

Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.


A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.

Huang Y, Burns DJ, Rich BE, MacNeil IA, Dandapat A, Soltani SM, Myhre S, Sullivan BF, Furcht LT, Lange CA, Hurvitz SA, Laing LG.

Oncotarget. 2016 Nov 29;7(48):78577-78590. doi: 10.18632/oncotarget.12480.


Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.

Malm M, Frejd FY, Ståhl S, Löfblom J.

MAbs. 2016 Oct;8(7):1195-1209. Epub 2016 Aug 17. Review.


HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Wang D, Qian G, Zhang H, Magliocca KR, Nannapaneni S, Amin AR, Rossi M, Patel M, El-Deiry M, Wadsworth JT, Chen Z, Khuri FR, Shin DM, Saba NF, Chen ZG.

Clin Cancer Res. 2017 Feb 1;23(3):677-686. doi: 10.1158/1078-0432.CCR-16-0558. Epub 2016 Jun 29.


The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.

Le Clorennec C, Lazrek Y, Dubreuil O, Larbouret C, Poul MA, Mondon P, Melino G, Pèlegrin A, Chardès T.

Oncotarget. 2016 Jun 14;7(24):37013-37029. doi: 10.18632/oncotarget.9455.


Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.

Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, Di Gennaro E, Ciliberto G, Roscilli G, Aurisicchio L, Marra E, Mancini R, Budillon A, Leone A.

Oncotarget. 2016 Apr 12;7(15):19559-74. doi: 10.18632/oncotarget.7195.


Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.

Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC.

Breast Cancer Res Treat. 2016 Feb;155(3):431-40. doi: 10.1007/s10549-016-3698-y. Epub 2016 Feb 9.

Supplemental Content

Support Center